Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $284.47 -1.65%
Revenue Growth %: -32.2%
Financial Fact:
Total other income (expense), net: -4.26M
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: -32.2%
Financial Fact:
Total other income (expense), net: -4.26M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.20), $0.21 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.9 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
